MCRB, US81750R2013

Seres Therapeutics leaves S&P Global BMI Index. Seres Therapeutics stock gains 1.16 percent

Published on 10/05/2026 at 07:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Two analysts set an average target of USD 17.00. Seres Therapeutics stock costs EUR 2.62 on October 5, 2026 after EUR 2.59.

MCRB, US81750R2013, Illustration mit AI erstellt.

Seres Therapeutics (ISIN US81750R2013) was trading at EUR 2.62 at Lang & Schwarz on October 5, 2026 at 7:50 a.m. CEST, up 1.16 percent versus the prior close of EUR 2.59. MarketScreener reported on September 20, 2026 that the Nasdaq-listed biotechnology company was removed from the S&P Global BMI Index. The index change adds a measurable market-structure event to a company already defined by clinical development and limited cash resources.

Index removal meets a 1.16 percent gain

The index change is the latest dated corporate-market event for Seres. MarketScreener identified Seres Therapeutics as Nasdaq-listed under ticker MCRB and reported the removal from the S&P Global BMI Index on September 20, 2026.

The same MarketScreener page listed two analysts with a Buy consensus and an average target of USD 17.00. Its displayed target was based on a last close of USD 3.79, a separate USD reference from the October 5 Lang & Schwarz price, so the two currencies and venues should not be combined into one return calculation.

Revenue doubled in the second quarter

Investing.com reported that revenue in the second quarter of 2026 was USD 736,000, up from USD 358,000 in the first quarter. That is a 105.59 percent quarter-over-quarter increase, although the operating result remained a USD 21.273 million loss in the second quarter.

Net income was USD 4.581 million in the second quarter, compared with a USD 19.913 million net loss in the first quarter. Operating cash flow was negative USD 22.394 million in the second quarter, while cash and cash equivalents stood at USD 15.594 million on June 30, 2026. The combination shows why reported net income and operating funding needs point in different directions.

Clinical progress meets funding pressure

Quartr summarized Seres material presented on September 15, 2026, including a 77 percent reduction in bloodstream infections for SER-155 in stem-cell transplant patients and an 80 percent immunosuppressive-free response in immune-related enterocolitis. Those figures support the pipeline case, but they remain clinical-development metrics rather than commercial revenue.

Seres said on June 5, 2026, in its investor-relations update, that two transactions strengthened its balance sheet, reduced ongoing lease costs and extended the projected operating cash runway well into the first quarter of 2027. The funding horizon remains central because second-quarter operating cash flow was negative USD 22.394 million.

MCRB trades above its prior close

Seres Therapeutics was trading at EUR 2.62 at Lang & Schwarz on October 5, 2026 at 7:50 a.m. CEST, plus 1.16 percent versus the Lang & Schwarz prior close of EUR 2.59 on October 2, 2026.